Doxorubicin

Generic Name
Doxorubicin
Brand Names
Adriamycin, Doxil, Myocet, Caelyx pegylated liposomal, Zolsketil pegylated liposomal, Myocet liposomal (previously Myocet), Celdoxome pegylated liposomal
Drug Type
Small Molecule
Chemical Formula
C27H29NO11
CAS Number
23214-92-8
Unique Ingredient Identifier
80168379AG
Background

Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970. Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its deta...

Indication

Doxorubicin is indicated for the treatment of neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin and non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue and bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinom...

Associated Conditions
AIDS-related Kaposi's Sarcoma, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Advanced Endometrial Cancer, Advanced Ovarian Cancer, Breast Cancer, Hodgkin's Lymphoma, Metastatic Bone Sarcomas, Metastatic Breast Cancer, Metastatic Soft Tissue Sarcoma, Metastatic Thyroid Cancer, Metastatic Urothelial Cancer, Multiple Myeloma (MM), Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Sezary Syndrome, Waldenström's Macroglobulinemia (WM), Advanced Thymoma, Advanced uterine sarcoma, Metastatic Bronchogenic Carcinoma, Metastatic Gastric carcinoma, Metastatic Neuroblastoma, Metastatic Ovarian carcinoma, Metastatic Wilms' tumor
Associated Therapies
-
Clinical Trials
Related News

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

First Posted Date
2023-08-08
Last Posted Date
2023-08-08
Lead Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Target Recruit Count
196
Registration Number
NCT05981014
Locations
🇨🇳

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil

First Posted Date
2023-07-25
Last Posted Date
2023-09-08
Lead Sponsor
Instituto do Cancer do Estado de São Paulo
Target Recruit Count
180
Registration Number
NCT05959720
Locations
🇧🇷

Instituto do Cancer do Estado de Sao Paulo, São Paulo, SP, Brazil

FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma

First Posted Date
2023-07-06
Last Posted Date
2023-07-06
Lead Sponsor
Fate Therapeutics
Registration Number
NCT05934097

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

First Posted Date
2023-07-03
Last Posted Date
2024-10-31
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
2400
Registration Number
NCT05929768
Locations
🇺🇸

Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States

🇺🇸

Cedars Sinai Medical Center, Los Angeles, California, United States

🇺🇸

Cancer Center of Kansas-Independence, Independence, Kansas, United States

and more 427 locations

PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma

First Posted Date
2023-06-28
Last Posted Date
2024-11-20
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
50
Registration Number
NCT05922904
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL

First Posted Date
2023-06-12
Last Posted Date
2023-06-12
Lead Sponsor
Ruijin Hospital
Target Recruit Count
332
Registration Number
NCT05899621
Locations
🇨🇳

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China

Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer

First Posted Date
2023-05-24
Last Posted Date
2023-05-25
Lead Sponsor
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Target Recruit Count
82
Registration Number
NCT05872412
Locations
🇧🇩

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

First Posted Date
2023-05-08
Last Posted Date
2023-11-29
Lead Sponsor
University of Birmingham
Target Recruit Count
284
Registration Number
NCT05848765
Locations
🇬🇧

Cardiff and vale University LHB, Cardiff, United Kingdom

🇬🇧

Belfast Health & Social Care Trust, Belfast, United Kingdom

🇬🇧

NHS Grampian, Aberdeen, United Kingdom

and more 22 locations

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

First Posted Date
2023-04-24
Last Posted Date
2024-11-25
Lead Sponsor
GI Innovation, Inc.
Target Recruit Count
358
Registration Number
NCT05824975
Locations
🇺🇸

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

🇺🇸

Mayo Clinic in Florida, Jacksonville, Florida, United States

🇺🇸

Mayo Clinic in Minnesota, Rochester, Minnesota, United States

and more 7 locations

Phase I/II of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue Sarcomas

First Posted Date
2023-04-12
Last Posted Date
2024-01-22
Lead Sponsor
Grupo Espanol de Investigacion en Sarcomas
Target Recruit Count
152
Registration Number
NCT05809830
Locations
🇪🇸

Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain

🇪🇸

Hospital Universitario La Paz, Madrid, Spain

🇪🇸

Hospital Clínico San Carlos, Madrid, Spain

and more 3 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy